Vivoryon Therapeutics N.V. to Present at Upcoming Investor Conferences

Group 1 - Vivoryon Therapeutics N.V. is a clinical stage biotechnology company focused on developing small molecule medicines for inflammatory and fibrotic disorders, primarily targeting kidney diseases [2][3] - The company will present at two upcoming investor conferences: the mwb online Health Care Conference on July 1, 2025, and the H.C. Wainwright 4th Annual Kidney Virtual Conference on July 14, 2025 [1][2] - The management team attending these conferences includes Frank Weber, CEO, and Julia Neugebauer, COO [1][2] Group 2 - Vivoryon's most advanced program, varoglutamstat, is a proprietary, first-in-class orally available QPCT/L inhibitor being evaluated for the treatment of diabetic kidney disease [2] - The company aims to improve patient outcomes by modulating the activity and stability of pathologically relevant proteins [2]